Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?

TheMotleyFool

0 0

Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?: https://g.foolcdn.com/editorial/images/757756/investor-stock-charts-screens-getty.jpg

Gene editing pioneer CRISPR Therapeutics (NASDAQ: CRSP) passed a major milestone on Dec. 8. The U.S. Food and Drug Administration (FDA) approved its first therapy, Casgevy, to treat patients with sickle cell disease.

The medical community cheered, but the stock market's response caught many investors off guard. Instead of shooting higher, CRISPR Therapeutics stock fell 8% on the day of its big announcement.

Is CRISPR Therapeutics a good biotech stock to buy on the recent dip? To answer that, we need to understand what its new therapy can and can't do.

Source Fool.com

Like: 0

CRSP

Share